New World Development's HK$25 Billion Rights Issue Backed by Full Underwriting from Chow Tai Fook Enterprises, HSBC and DBS

Stock News11-16 09:12

Major developments: New World Development (00017) is raising approximately HK$25 billion through a rights issue, with Chow Tai Fook Enterprises, together with HSBC and DBS Bank, fully underwriting the offering, signaling strong confidence.

Jingjin New Energy (01783) signed a computing power service framework agreement, securing supply of over 30,000 GPUs, reinforcing the rationale for compliant computing power leasing and improving the economics of its rental business.

Insilico Medicine (03696) entered into a strategic AI pharmaceutical collaboration with Luoxin Pharmaceutical (002793.SZ), focusing on innovative drug R&D for chronic diseases including digestive and metabolic conditions.

China Ruyi (00136) is deepening its AI strategic layout: jointly launching a professional film and television AIGC workflow called "Yuanpai" and co-building vertical film and television large models and world models.

China Boton (03318) subsidiary is injecting RMB 160 million into Shandong Ganghong Biotechnology to acquire a 49% stake.

Hengrui Pharmaceuticals (01276): drugs including SHR-4610 injection received drug clinical trial approval notices.

Gofintech Quant (00290) plans to sell a 22.50% stake in Southern Dongying Asset Management Limited for HK$1.2 billion, focusing on its own dedicated public fund business.

Grand Pharma (00512): six products successfully included in the 2026 National Medical Insurance Drug Catalog, the Commercial Insurance Innovative Drug Catalog, and industry supporting lists.

Pegbio Biopharma-B (02565): core product Paidakang® (vepaglutide injection) successfully included in the 2026 National Medical Insurance Drug Catalog.

Fosun Pharma (02196): multiple products newly included in the National Medical Insurance Catalog.

Luye Pharma (02186): Ruoxinlin® successfully renewed in the National Medical Insurance Drug Catalog.

JW Therapeutics-B (02126): Benoda® (relma-cel injection) included in the National Basic Medical Insurance Drug Catalog.

Innovent Biologics (01801): seven innovative products including Xinermei® and Xinmeiyue® successfully included in the 2026 edition of the National Medical Insurance Drug Catalog.

Henlius Biotech (02696): Hansizhuang® and Futuoning® new indications included in the National Medical Insurance Drug Catalog.

Xuanzhu Biopharma-B (02575): pyrrolitinib new indication included in the 2026 National Basic Medical Insurance Drug Catalog.

Dongyangguang Pharma (06887): Ologliptin capsules successfully included in the 2026 edition of the National Medical Insurance Drug Catalog.

Hansoh Pharma (03692): all approved indications of its marketed innovative drugs have been included in the medical insurance catalog.

Hengrui Pharmaceuticals (01276): certain products included in the 2026 National Medical Insurance Catalog.

Beihai Kangcheng-B (01228): Gereining® and Mairuibei® included in the first edition of the Commercial Health Insurance Drug Guarantee Cost List.

Simcere Pharma (02096): Xianbixin® sublingual tablets included in the new edition of the National Medical Insurance Drug Catalog.

Ascentage Pharma (06855): Lishengto® successfully included in the 2026 National Medical Insurance Drug Catalog; Nailike® renewed.

Everest Medicines (01952): Weishiping® and Yijia® successfully included in the 2026 new edition of the National Medical Insurance Drug Catalog.

Junshi Biosciences (01877): Tuoyi® new indication included in the National Medical Insurance Catalog.

Operating results: Goodbaby International (01086) reported revenue of approximately HK$6.926 billion for the first three quarters, up 7.9% year-on-year.

China Metallurgical (01618) signed new contracts worth RMB 548.75 billion in the first 10 months.

IBI Group Holdings (01547) issued a positive profit alert, expecting interim net profit to increase to approximately HK$13.8 million year-on-year.

China Education Group (00839) expects annual net profit attributable to shareholders of approximately RMB 630 million to RMB 770 million.

Hong Kong Technology Venture (01137) reported October Hong Kong e-commerce business order gross merchandise value of HK$768 million, up 11.6% year-on-year.

IES Holdings (01656) reported first three quarters revenue of S$397.5 million, a historical high, with profit attributable to shareholders up 434.7% year-on-year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment